US biopharmaceutical giant Gilead Sciences NASDAQGILD will drop simtuzumab from the ongoing development of its fatty liver disease treatment GS4997.Gilead announced a couple of weeks ago that it would be advancing the treatment also known as selonsertib ...
↧